Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Accepts Morphotek's IND | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Accepts Morphotek’s IND

For MORAb-202, an antibody-drug conjugate (ADC), to treat solid tumors

By: Betsy Louda

, Contract Pharma

Morphotek, a subsidiary of Eisai Inc., announced today that the U.S. Food and Drug Administration accepted an Investigational New Drug (IND) Application for MORAb-202, an antibody-drug conjugate (ADC), to treat solid tumors that express folate receptor alpha (FRA).  

 

A Phase 1 dose-escalation study will be conducted in the U.S. to evaluate the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express FRA.  The solid tumors to be studied include advanced or metastatic endometrial, non-small cell lung, ovarian and triple-negative breast cancer.

 

MORAb-202 is a novel investigational ADC that uses a cathepsin-cleavable linker to combine investigational farletuzumab with the microtubule inhibitor payload, eribulin.  Eribulin mesylate (Halaven) is approved in the U.S. for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting.

 

“We are pleased that the FDA has accepted our IND application to study MORAb-202, an antibody-drug conjugate that combines farletuzumab with the regulatory-approved eribulin, in solid tumors that express folate receptor alpha,” said Nicholas Nicolaides, president and chief executive officer of Morphotek. “This investigational agent has shown robust antitumor effects in a number of preclinical FRA-expressing tumor models, making it a potential promising candidate for the treatment of cancers that express this biomarker.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics